Skip to main content
Premium Trial:

Request an Annual Quote

Creative Bioinformatics Consultants Taps Gataca's Solutions for NGS Projects


NEW YORK (GenomeWeb) – This week, Gataca, a software development company, said that Creative Bioinformatics Consultants, a fee-for-service bioinformatics consulting firm, has selected its OneGenomeBox and HepCbase solutions to share, store, collaborate, and analyze next-generation sequencing data in its clients' projects.

According to the companies, the partnership will let Creative Bioinformatics leverage the power, user-friendliness, and collaborative capabilities in the Gataca platform to provide project specific data analyses to its customers. Founded in 2013, the consultancy's network of bioinformatics experts serves clients in academic laboratories, biotechnology companies, and pharmaceutical organizations that lack the expertise or resources to perform their own analysis in-house.

Gataca's OneGenomeBox contains tools for managing, storing, and visualizing data that among other things, lets users evaluate raw read quality, as well as trim and filter reads based on parameters such as N content, log changes, and GC bias. HepCBase, is a version of OneGenomeBox that is tailored for analyzing sequence data from the hepatitis C virus. Among other features, it has tools for HCV genotyping, phylogenetic analysis, and analyzing and reporting genetic mutations. The software has two modules; one designed for use with Sanger sequence, and a second specifically for exploring NGS data.

Johanna Craig, Gataca's CEO, told BioInform via email that Creative will use several data sharing and analysis components in her firm's solutions that have been tested but not vetted as yet. "We are providing these capabilities in exchange for a special price and exchange for gaining usability and feedback from a large number of users via their portal," she said.

Gataca plans a full launch of OneGenomeBox at the end of the fourth quarter of this year following a beta test. They plan to launch HepCBase sometime next year following a beta test.

Filed under